Safety of a new spray-type adhesion barrier (AdSpray® ) in liver surgery
Satoshi Okubo1, Junichi Shindoh1,2, Yuta Kobayashi1
1Hepato-Biliary-Pancreatic Surgery Division, Department of Gastroenterological Surgery, Toranomon Hospital, Minatoku, Japan.
Background:
Although adhesion barriers are increasingly used in liver surgery, there are no sufficient data yet in support of their safety.
Methods:
Data of 104 consecutive patients in whom a spray-type adhesion barrier (AdSpray® ) was used after hepatectomy were compared with those of 94 control subjects in whom no adhesion barriers were used, and the risk factors for major morbidity after hepatectomy were investigated.
Results:
The incidence of major morbidity was not significantly different between the AdSpray group and the control group (17% vs 15%, P = .645), although multivariate analyses revealed that the use of AdSpray was associated with an increased risk of abdominal abscess (odds ratio [OR], 4.42; P = .043). Similar tendency was also confirmed after propensity score adjustment to account for the potential selection bias. A sub-group analysis revealed that incidence of abscess formation decreased as operators' experience in the used of AdSpray increased, and multivariate analysis identified preoperative chemotherapy (OR, 3.96; P = .043) as being independent predictors of abscess formation after the use of AdSpray.
Conclusions:
AdSpray use was not associated with global incidence of major morbidity after liver surgery, although surgeon's experience would be needed for adequate use of AdSpray to minimize the risk of postoperative abscess formation.
